Alimera makes deal with Emory

Article

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

The agreement gives Alimera the exclusive option to license a unique class of compounds, NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidise inhibitors, as a potential treatment for conditions such as dry age-related macular degeneration (AMD).

Alimera will also receive the exclusive rights to sublicense in ophthalmology and the exclusive rights for non-ophthalmic use. The company will be responsible for the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.